Tough first quarter for Takeda as US Prevacid sales slump
This article was originally published in Scrip
Executive Summary
Global sales of Takeda's top product, Actos (pioglitazone), were up by 4% to ¥99.5 billion ($1.14 billion) in the first quarter to 30 June, helped by a solid performance in the US, where sales of the oral antidiabetic rose by 12% to $854 million.